Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

This week's roundup of Houston innovators includes Jason Bock of CTMC, Barbara Burger, and Mario Amaro of Ease. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from cell therapy to energy transition — recently making headlines in Houston innovation.

Jason Bock, founder and CEO of CTMC

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Last year, a project out of MD Anderson spun out to create a new joint venture, CTMC — Cell Therapy Manufacturing Center, with National Resilience, a company that was founded to help advance life-saving therapeutics. The JV is based in the Texas Medical Center and led by CEO Jason Bock, who says the entity's location is critical.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Read more.

Barbara J. Burger, startup adviser and mentor 

Energy innovation expert, Barbara Burger, shares how she sees the future of energy playing out as a dance between mice — the startups — and elephants — the incumbent corporations. Photo courtesy

The way Barbara Burger sees it, the energy transition depends on a dance between startups, or the mice, and corporates, aka the elephants. In a guest column for InnovationMap, she explains what questions each side needs to address.

"There are lots of questions here and the why is often an iterative journey for both sides," she explains. "It is as much mindset, influence, strategy, champions, and risk tolerance at individual levels as it about technology and economics." Read more.

Mario Amaro, CEO and founder of Ease

Mario Amaro, founder of Ease, was selected for one of Amazon's accelerator programs. Photo courtesy of Amazon

Amazon's AWS Impact Accelerator Latino Founders Cohort named the 20 startups joining its accelerator that will connect Latinx founders to its network of mentors, provide programming, and even dole out funding.

Houston-based Ease, founded by Mario Amaro in 2018, the health care fintech platform allows for medical professionals to start, grow, and manage their private practices with bookkeeping tools and other software infrastructure. So far, the company has worked with more than 300 practices. Read more.

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Houston innovator aims to scale cancer-curing cell therapies

HOUSTON INNOVATORS PODCAST EPISODE 185

It's almost unreal what can be done with therapeutics today, especially in the specialty of cell therapy.

"It feels like science fiction," says Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, or CTMC, a joint venture between National Resilience and MD Anderson Cancer Center.

Cell therapy is essentially personalized medicine, he explains. The process includes taking out a patient’s own immune cells, identifying specifically the T-cells, and engineer them to have them target cancer before expanding them and reintroducing them to the patient.

“The supply chain begins with the patient,” Bock explains on the Houston Innovators Podcast. “If the patient is going to be an integral part of the supply chain, one way to simplify your supply chain is to locate your manufacturing very close to where your patients are.”

That's where CTMC, located in the heart of the Texas Medical Center, comes in. Bock moved to Houston from the East Coast four years to stand up the program at MD Anderson. The founding thesis was to work with faculty members who have interesting ideas for biologics or cell therapies, help them industrialize them, and then bring them into the MD Anderson clinic to evaluate in patients.

Last year, the entity spun out into a joint venture structure with National Resilience, a company that was founded amid the pandemic to build resilience in the nation for complex biologics manufacturing — like vaccines, for instance — in order to expedite the process of getting these treatments to patients.

With access to patients established, how do you address scalability of this treatment in a field that's so customized?

While it might sound like a challenge to scale personalized medicine — it's a worthwhile challenge. Bock says that even though cell therapy is in its early stages still — the first treatment was approved by the FDA just five years ago — early studies have shown patients, who essentially have no other treatment options, can see life-saving results in as little as one treatment.

"We see in a large group of patients — 30 to 50 percent of patients — are cured with one dose," he says on the show.

CTMC has a 60,000-square-foot space two blocks away from MD Anderson. This critical lab space with 14 clean rooms was made available after its previous biotech tenant moved out. The setup can support up to 140 people, and the organization has grown to 80 people over the past few years.

Bock says CTMC is an engine for cell therapy research — one that can take a therapeutic from research to the clinic in about one to two years. Every year, he says CTMC can roll three to five therapeutics into the clinic phase.

And, Houston's an ideal place to do that.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UTMB launches new department for space medicine, names inaugural leader

department launch

In space, no one can hear you scream—but they can hear you discuss your medical history and recent symptoms.

The University of Texas Medical Branch (UTMB) announced last month that it would form a new Department of Aerospace and Exploration Medicine within its School of Public and Population Health under the leadership of Dr. Ronak V. Shah, who will serve as inaugural chair.

“Human exploration is changing rapidly, and the health challenges associated with distance, isolation, and limited resources are changing along with it,” Shah said in a news release. “Creating the Department of Aerospace and Exploration Medicine gives us an opportunity to build on decades of expertise at UTMB as we prepare for the future.”

The new department elevates UTMB’s existing Aerospace Medicine Division and provides "broader academic structure for expanding research, education, and collaboration across disciplines," according to the release. Shah was previously named director of the division in 2022 after serving as medical director of Johnson Space Center.

Space exploration in particular has a wide variety of highly specific medical side effects that are in need of the formalized study that the department will specialize in. For example, zero- and low-gravity environments cause everything from detached fingernails to flattened eyeballs. Even in modern, high-tech spacecraft, the human body feels the impacts of space.

It’s an area of medicine UTMB is uniquely suited for. Starting in the 1950s with NASA’s director of medical research Dr. Charles A. Berry, UTMB partnered with the blossoming era of exploration by monitoring astronauts. In 1993, UTMB and the NASA Johnson Space Center created the joint Aerospace Medicine Residency Program, which used bed facilities at the Galveston branch to simulate weightlessness. Wherever there has been a question about how flight and space affect health, odds are UTMB has been involved.

The Department of Aerospace and Exploration Medicine will launch several new initiatives soon. One planned for 2027 is an Undersea and Hyperbaric Medicine Fellowship that will allow scientists to study the physiology of high-pressure flight.

“In the era of a growing global space economy, we are revisiting questions such as who is flying, what is their destination, what vehicle will get them there?” Shah added in the release. “The answers to these questions will drive what research is needed and how we train the next generation.”

Energy AI company opens first U.S. office at Houston's the Ion

new to hou

Building on its partnership with Houston-based oilfield services provider Halliburton, energy-sector AI company Shape Digital recently opened an office at The Ion. It’s the company’s first U.S. location.

Shape Digital’s workforce in Houston includes employees specializing in tech support, business development and client services. The company’s local hiring projections and headcount weren’t available. The new office will be located within Industrious at the Ion, according to Rice Alliance.

A key driver of the new Houston office: The company forecasts North America will account for more than 20 percent of its business in 2027.

“North America is a critical market for industrial innovation, and Houston sits at the center of companies driving that progress,” Caio Sene, vice president of client services at Shape Digital, said in a release. “Growing our presence here allows us to work alongside operators as they look for practical ways to turn existing operational data into clear recommendations for what to do next.”

Shape Digital, which also has offices in Singapore and Brazil, develops decision-making platforms for the oil and gas sector.

The Ion District office gives Shape Digital a presence close to Halliburton’s headquarters. In May, the two companies forged a partnership to combine Halliburton’s Digital Field Solverdecision-making system with Shape Digital’s AI portfolio.

Shape Digital layers AI software atop existing operations data rather than replacing legacy systems or adding new software.

The company’s suite of AI agents draws on more than 200 operations-monitoring algorithms, continually learning from company and industry data. The suite comprises four products: Shape Aura, Shape Lighthouse, Shape Lumen and Shape Reef.

Shape Digital says that by working with a customer’s existing operations data, it can deliver ROI in less than two months without any additional investment in equipment or infrastructure.

The company is a 2021 spinoff of Japan-based Modec. Modec builds, owns, and operates floating offshore oil and gas production facilities. Its Modec America subsidiary is based in Houston.

Meet the esteemed judges for the 2026 Houston Innovation Awards

Meet The Judges

Editor's note: Judging is now underway for the 2026 Houston Innovation Awards, and it's time to meet the decision makers.

Our 2026 judging panel comprises past award winners who represent a variety of industries and areas of expertise. They are joined by InnovationMap's interim editor. All are deeply engaged in the Houston innovation ecosystem.

Our judging panel will review all nominee applications submitted across 10 prestigious categories. They will determine the 2026 finalists in all categories, and they will select the winners in all but one category — our people's choice award for Startup of the Year.

The sixth annual Houston Innovation Awards program will be presented in an all-digital format in 2026. We will announce this year's finalists and feature their stories throughout our special editorial series this fall. Then, stay tuned as we reveal the 2026 Houston Innovation Awards winners on InnovationMap.com in mid-November.

Sagar Dalal, Fervo Energy, 2025 Scaleup of the Year

Sagar Dalal

Sagar Dalal serves as chief of staff at Fervo Energy, a company pioneering the commercialization of next-generation geothermal power. In this role, he helps translate the CEO’s vision and priorities into execution, leading cross-functional strategic initiatives that support the company’s growth and operations.

Dalal brings nearly eight years of experience in structural engineering and project management from his time at Thornton Tomasetti and Tesla, where he engineered and built a wide range of infrastructure projects ranging from stadiums to manufacturing facilities. He holds an MBA from Stanford University and an MS in Civil Engineering from Texas A&M University. He is also a licensed professional engineer.

Aaron Fitzgerald, Mars Materials, 2025 Minority-founded Business of the Year

Aaron Fitzgerald

Aaron Fitzgerald is a three-time founder and carbon removal entrepreneur focused on reimagining how we make things. As the CEO of Mars Materials, he leads a team working to commercialize technologies that sequester captured carbon into industrial supply chains.

His vision for a defossilized future is shaped by a unique path through both policy, including a tenure in the United States Senate, and deep carbontech, with fellowships at The Lewis Latimer program, Breakthrough Energy, Prime Coalition, and Carbon 180.

Tatiana Fofanova, Koda Health, 2025 Health Tech Business of the Year

Tatiana Fofonova

Tatiana Fofanova, PhD, is the co-founder and CEO of Koda Health, an AI-enhanced patient decision support platform designed to make advance care planning (ACP) scalable, accessible, and patient-centered for patients with serious illness.

After earning her PhD in Translational Medicine at Baylor College of Medicine, she joined Texas Medical Center (TMC) as a Founder-in-Residence. It was there that she and her co-founders identified one of the most overlooked yet critical gaps in healthcare: the lack of meaningful, accessible advance care planning. Under her leadership, Koda Health now supports over 1 million patients through partnerships with organizations like Cigna, Privia, and Houston Methodist.

Lawson Gow, Greentown Labs, 2025 Incubator/Accelerator of the Year

Lawson Gow currently serves as chief strategy officer for Greentown Labs, which was named Incubator/Accelerator of the Year in the 2025 Houston Innovation Awards. Prior to joining Greentown Labs as Head of Houston in 2025, Gow was as a managing partner at Helium Capital, an investment and advisory firm that aims to support founders across the entire lifecycle of entrepreneurship.

He is also the founder of The Cannon, an innovation-infrastructure provider that operates a growing network of innovation hubs for its community of startups, entrepreneurs, investors, and corporate innovators.

Sarah Hein, March Biosciences, 2025 Female-founded Business of the Year

Sarah Hein

Sarah Hein is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging malignancies. Prior to cofounding March Biosciences, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT).

Formerly, she was a cofounder and the vice president of operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.

Tanu Jain, FlowCare, 2025 Startup of the Year

Tanu Jain

Tanu Jain is a product executive, entrepreneur, founder and CEO of FlowCare, and registered nurse with a track record of building products from zero to global scale. She previously led product at BioIQ before founding FlowCare, a Houston-based period care infrastructure platform making period care a standard in every restroom. In under 16 months, FlowCare has signed deployed across four enterprise customers and impacted more than 1.5 million women.

FlowCare was named Startup of the Year at the 2025 Houston Innovation Awards, and Jain has been recognized with additional honors including the SDG Super Changemaker – Pewter — at the Global Sustainability Awards 2026.

Prabhdeep "Prab" Sekhon, Eclipse Energy, 2025 Energy Transition Business of the Year

Prabhdeep Singh Sekhon

Prabhdeep Singh Sekhon is CEO of Eclipse Energy, an energy technology company transforming depleted oil fields into low-cost, sustainable hydrogen resources through subsurface biotechnology. He brings nearly two decades of global energy experience spanning climate technology, venture capital, private equity, and multi-billion-dollar energy projects across five continents.

Previously, he held leadership roles at NextEra Energy Resources and Hess Corporation. He is also a founder and managing director of GreenLite Resources and a founding member of Cotogna Sports Group. He holds an MBA from Wharton, a Masters in Engineering from Texas A&M, and a BS from the University of Calgary.

Wade Pinder, Product Houston, 2025 Trailblazer Award Winner

Wade Pinder thinks of himself as an "ecosystem wayseeker," helping founders and builders in and around Houston find their footing, understand the landscape, and move through uncertainty with more clarity. Through Product Houston, he works at the intersection of product strategy, founder support, ecosystem mapping, and community-building, with a particular focus on helping people show up in the right rooms before they feel fully ready.

His background includes years in product management at Blinds.com and Home Depot, along with founding and leading the Houston Product Community for six years. He was recognized by as Mentor of the Year in the 2023 Houston Innovation Awards and received the Trailblazer Award in 2025.

Laura Furr Mericas, Interim Editor, InnovationMap

Laura Furr Mericas is interim editor for InnovatonMap.com and EnergyCapitalHTX.com. She is a longtime contributor to both sites and has reported on Houston's innovation ecosystem for InnovationMap since 2020. Previously, she served as web editor and data reporter for Houston Business Journal.